Somatuline Depot

Given existing treatment options, and because gastroenteropancreatic neuroendocrine tumors (NETs) tend to be an indolent disease and many patients remain asymptomatic, there is a lack of urgency in initiating treatment. The launch campaign introduces and highlights an icon for the disease—a charging turtle. In the core visual, the turtle lunges forward…but is held back by the SOMATULINE harness. The core headline highlights the ability of SOMATULINE to hold back progression, and it establishes progression-free survival as a new standard in measuring success in the treatment of NETs.

Rx Award Of Excellence
Please click here for Patient Information and full Prescribing Information.